Viking Therapeutics Q1 2026: Subcutaneous Phase 3 Fully Enrolled, but Oral VK2735 Phase 3 Start Pushed to 4Q26

What happened

Viking Therapeutics reported Q1 2026 financial results, highlighting that both VANQUISH-1 and VANQUISH-2 Phase 3 trials for subcutaneous VK2735 are now fully enrolled. However, the initiation of the oral VK2735 Phase 3 trial for obesity has slipped from the previously guided 3Q26 to 4Q26, a notable delay. The maintenance dosing study remains on track with data expected in 3Q26, which will be critical for assessing tolerability improvements. The company also filed an IND for a novel amylin agonist, VK3019, with Phase 1 initiation expected in 2Q26. Cash position stood at $603 million, down from $706 million at year-end 2025, reflecting continued burn as the pipeline advances.

Implication

The delay in oral VK2735 Phase 3 initiation from 3Q26 to 4Q26 introduces incremental timeline risk, likely compressing the stock's valuation multiple until the 3Q26 maintenance data readout. Investors should scrutinize the maintenance data for signs of improved tolerability versus the Phase 2 oral profile; a positive result could mitigate the delay's impact. The fully enrolled subcutaneous program provides a floor, but the stock's premium relies on oral optionality. With cash lasting into late 2026 at current burn, no near-term dilution is expected, but any further delays could trigger a reassessment.

Thesis delta

The shift of oral VK2735 Phase 3 start from 3Q26 to 4Q26 reduces near-term catalyst density and slightly elevates timeline risk. While the subcutaneous program advances as expected, the oral delay may compress valuation multiples until the 3Q26 maintenance data and 4Q26 initiation. The bull case now depends on positive maintenance data and no further delays.